Meridian Bioscience Graham Number
The Graham Number of Meridian Bioscience (VIVO) as of Oct 9, 2026 is 13.36 USD. In the previous year, Graham Number was 16.43 USD — a change of -18.69% (lower).
Get this data via API
Financial Data API
Graham Number
13.36USD
YoY
-18.69%
Last updated:
Graham Number of Meridian Bioscience is 2022 13.36 USD. Graham Number of Meridian Bioscience was 2021 16.43 USD. It decreases by -18.69% lower compared to the previous year.
The Meridian Bioscience Graham Number history
3 Years
10 Years
25 Years
Max
Graham Number
Date
Graham Number
Jan 1, 2015
8.46 USD
Jan 1, 2016
8.01 USD
Jan 1, 2017
6.62 USD
Jan 1, 2018
6.99 USD
Jan 1, 2019
7.43 USD
Jan 1, 2020
11.59 USD
Jan 1, 2021
16.43 USD
Jan 1, 2022
13.36 USD
| YEAR | Graham Number | YoY |
|---|---|---|
| 13.36USD | -18.69% | |
| 16.43USD | +41.79% | |
| 11.59USD | +56.00% | |
| 7.43USD | +6.23% | |
| 6.99USD | +5.61% | |
| 6.62USD | -17.32% | |
| 8.01USD | -5.27% | |
| 8.46USD | +2.73% | |
| 8.23USD | — |
Access this data via the Eulerpool API
Meridian Bioscience Stock analysis
What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Meridian Bioscience stock
Graham Number of Meridian Bioscience is 13.36 USD in 2022.
On Eulerpool you can find the complete historical development of Graham Number Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.
The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.
Access this data via the Eulerpool API
Quality — Meridian Bioscience
All Key Metrics — Meridian Bioscience
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth